CAMBRIDGE, Mass. — No one seems to quite know who gave Werewolf Therapeutics its name. But it’s very clear where the new startup, founded in 2017 by MPM Capital, got its lab space and its staff: Potenza Therapeutics.

Potenza’s lab space at 1030 Massachusetts Ave. has barely had time to get cold after Japanese drug maker Astellas (ALPMY) acquired the company in December, but the company’s former leadership team is planning to move back in as Werewolf on April 1, the company’s vice president of research and development, Cynthia Seidel-Dugan, told Cambridge regulators on Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy